Free Trial

ZyVersa Therapeutics (ZVSA) Short Interest Ratio & Short Volume

ZyVersa Therapeutics logo
$0.14 -0.04 (-22.54%)
As of 04:00 PM Eastern

ZyVersa Therapeutics Short Interest Data

ZyVersa Therapeutics (ZVSA) has a short interest of 4.99 million shares, representing 9.24% of the float (the number of shares available for trading by the public). This marks a 2,541.61% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.1, indicating that it would take 7.1 days of the average trading volume of 2.47 million shares to cover all short positions.

Current Short Interest
4,990,000 shares
Previous Short Interest
188,900 shares
Change Vs. Previous Month
+2,541.61%
Dollar Volume Sold Short
$3.38 million
Short Interest Ratio
7.1 Days to Cover
Last Record Date
June 30, 2025
Outstanding Shares
4,870,000 shares
Float Size
54,030,000 shares
Short Percent of Float
9.24%
Today's Trading Volume
635,472 shares
Average Trading Volume
2,474,194 shares
Today's Volume Vs. Average
26%
Short Selling ZyVersa Therapeutics?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for ZyVersa Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

ZVSA Short Interest Over Time

ZVSA Days to Cover Over Time

ZVSA Percentage of Float Shorted Over Time

ZyVersa Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
6/30/20254,990,000 shares $3.38 million +2,541.6%9.2%7.1 $0.68
6/15/2025188,900 shares $123.20 thousand -37.2%4.0%0 $0.65
5/31/2025301,000 shares $195.05 thousand +35.8%6.3%0.1 $0.65
5/15/2025221,700 shares $113.73 thousand -38.8%4.7%0.1 $0.51
4/30/2025362,300 shares $220.97 thousand -28.8%10.0%0.1 $0.61
4/15/2025509,100 shares $397.00 thousand +364.1%14.1%0.2 $0.78
3/31/2025109,700 shares $69.11 thousand -41.6%4.3%0 $0.63
3/15/2025187,900 shares $148.42 thousand +323.2%7.5%0.2 $0.79
2/28/202544,400 shares $50.17 thousand -54.6%1.8%0.1 $1.13
2/15/202597,800 shares $121.27 thousand -24.5%4.2%0.1 $1.24
1/31/2025129,600 shares $180.14 thousand -53.2%5.5%0.2 $1.39
1/15/2025276,800 shares $390.29 thousand +1,291.0%11.8%0.1 $1.41
12/31/202419,900 shares $21.09 thousand -22.3%0.9%0 $1.06
12/15/202425,600 shares $26.89 thousand -34.4%1.1%0 $1.05
11/30/202439,000 shares $41.89 thousand +35.0%1.7%0 $1.07
11/15/202428,900 shares $31.21 thousand -36.5%2.7%0 $1.08
10/31/202445,500 shares $91.46 thousand +369.1%4.3%0 $2.01
10/15/20249,700 shares $22.31 thousand -59.2%0.9%0.1 $2.30
9/30/202423,800 shares $57.12 thousand +33.0%2.2%0.2 $2.40
9/15/202417,900 shares $39.02 thousand -63.9%1.7%0.1 $2.18
8/31/202449,600 shares $136.90 thousand +21.3%4.7%0.4 $2.76
8/15/202440,900 shares $123.52 thousand -27.2%4.0%0.3 $3.02
7/31/202456,200 shares $194.45 thousand +68.3%6.8%0.4 $3.46
7/15/202433,400 shares $147.29 thousand +76.7%4.0%0.1 $4.41
6/30/202418,900 shares $71.06 thousand -46.0%2.3%0.1 $3.76
6/15/202435,000 shares $183.75 thousand +797.4%4.2%0.2 $5.25
5/31/20243,900 shares $19.27 thousand -73.8%0.5%0 $4.94
5/15/202414,900 shares $73.61 thousand -4.5%1.8%0 $4.94
4/30/202415,600 shares $82.52 thousand -96.6%2.1%0 $5.29
4/15/2024460,800 shares $292.84 thousand -20.6%6.1%0.2 $0.64
3/31/2024580,600 shares $435.45 thousand -10.1%8.1%0.2 $0.75
3/15/2024646,000 shares $504.20 thousand -45.7%16.9%0.2 $0.78
2/29/20241,190,000 shares $1.31 million +619.5%74.4%0.4 $1.10
2/15/2024165,400 shares $95.40 thousand -14.5%10.3%0.1 $0.58
1/31/2024193,500 shares $110.31 thousand +545.0%1.5%0.2 $0.57
1/15/202430,000 shares $22.61 thousand -51.6%0.2%0 $0.75
12/31/202362,000 shares $55.80 thousand +38.1%0.5%0.1 $0.90
12/15/202344,900 shares $34.80 thousand +152.3%0.4%0.1 $0.78
11/30/202317,800 shares $40.50 thousand -99.2%0.1%0 $2.28
11/15/20232,300,000 shares $191.13 thousand +25.7%18.3%0.3 $0.08
Trump’s worst nightmare (Ad)

Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.

Watch the National Emergency broadcast here
10/31/20231,830,000 shares $150.06 thousand -26.8%14.6%0.3 $0.08
10/15/20232,500,000 shares $324.75 thousand +86.6%19.9%0.5 $0.13
9/30/20231,340,000 shares $173.53 thousand -63.1%10.7%0.3 $0.13
9/15/20233,630,000 shares $540.87 thousand +1,168.8%28.9%0.8 $0.15
8/31/2023286,100 shares $40.68 thousand -9.2%2.3%0.1 $0.14
8/15/2023315,100 shares $50.42 thousand -52.4%2.5%0.2 $0.16
7/31/2023662,600 shares $114.30 thousand -43.9%5.3%0.3 $0.17
7/15/20231,180,000 shares $293.47 thousand +148.0%N/A0.4 $0.25
6/30/2023475,900 shares $116.83 thousand -37.4%N/A0.2 $0.25
6/15/2023760,400 shares $250.93 thousand +6.7%N/A0.4 $0.33
5/31/2023712,400 shares $260.74 thousand +178.9%N/A0.4 $0.37
5/15/2023255,400 shares $110.41 thousand No ChangeN/A0.2 $0.43

ZVSA Short Interest - Frequently Asked Questions

What is ZyVersa Therapeutics' current short interest?

Short interest is the volume of ZyVersa Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 4,990,000 shares of ZVSA short. 9.24% of ZyVersa Therapeutics' shares are currently sold short. Learn More on ZyVersa Therapeutics' current short interest.

What is a good short interest ratio for ZyVersa Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ZVSA shares currently have a short interest ratio of 7.0. Learn More on ZyVersa Therapeutics's short interest ratio.

What is a good short interest percentage for ZyVersa Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 9.24% of ZyVersa Therapeutics' floating shares are currently sold short.

Is ZyVersa Therapeutics' short interest increasing or decreasing?

ZyVersa Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 4,990,000 shares, an increase of 2,541.6% from the previous total of 188,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is ZyVersa Therapeutics' float size?

ZyVersa Therapeutics currently has issued a total of 4,870,000 shares. Some of ZyVersa Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. ZyVersa Therapeutics currently has a public float of 54,030,000 shares.

How does ZyVersa Therapeutics' short interest compare to its competitors?

9.24% of ZyVersa Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ZyVersa Therapeutics: AlloVir, Inc. (2.56%), Sonnet BioTherapeutics Holdings, Inc. (1.32%), NextCure, Inc. (1.40%), Leap Therapeutics, Inc. (9.27%), IM Cannabis Corp. (12.28%), Synaptogenix, Inc. (12.63%), BioXcel Therapeutics, Inc. (6.08%), Minerva Neurosciences, Inc (0.50%), Phio Pharmaceuticals Corp. (7.19%), Bright Green Co. (0.04%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

What does it mean to sell short ZyVersa Therapeutics stock?

Short selling ZVSA is an investing strategy that aims to generate trading profit from ZyVersa Therapeutics as its price is falling. ZVSA shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against ZyVersa Therapeutics?

A short squeeze for ZyVersa Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ZVSA, which in turn drives the price of the stock up even further.

How often is ZyVersa Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ZVSA, twice per month. The most recent reporting period available is June, 30 2025.




This page (NASDAQ:ZVSA) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners